androgen receptor small interfering RNA

Androgen receptor small interfering RNA is a specific RNA-based therapy designed to silence the expression of the *androgen receptor* (AR) gene through the RNA interference (RNAi) pathway. It consists of small interfering RNA (siRNA) molecules engineered to target complementary mRNA sequences of the androgen receptor, leading to degradation of the transcript and reduction of AR protein levels. This mechanism inhibits androgen-dependent signaling, suppresses proliferation, induces apoptosis, and reduces angiogenesis in prostate cancer cells, particularly in both androgen-dependent and castration-resistant prostate cancer[1][3][4]. Preclinical studies show that intravenous administration of AR siRNA, often delivered via plasmid vectors or formulated for enhanced uptake (e.g., focused ultrasound-facilitated delivery), significantly reduces prostate tumor growth in vivo. The drug operates as a *gene therapy* modality and is generally considered in the context of experimental cancer therapeutics rather than as a marketed pharmaceutical product[1][3].

Other names

AR siRNAanti-androgen receptor siRNAandrogen receptor-targeted siRNA